D. Von-schweinitz, Hepatoblastoma: recent developments in research and treatment, Semin Pediatr Surg, vol.21, pp.21-30, 2012.

D. Lopez-terrada, R. Alaggio, M. T. De-davila, P. Czauderna, E. Hiyama et al., Towards an international pediatric liver tumor consensus classification: proceedings of the Los Angeles COG liver tumors symposium, Mod Pathol, vol.27, pp.472-491, 2014.

S. Cairo, C. Armengol, D. Reynies, A. Wei, Y. Thomas et al., Hepatic stem-like phenotype and interplay of Wnt/beta-catenin and Myc signaling in aggressive childhood liver cancer, Cancer Cell, vol.14, pp.471-484, 2008.

B. J. Allan, P. P. Parikh, S. Diaz, E. A. Perez, H. L. Neville et al., Predictors of survival and incidence of hepatoblastoma in the paediatric population, HPB (Oxford), vol.15, pp.741-746, 2013.

J. Zsiros, L. Brugieres, P. Brock, D. Roebuck, R. Maibach et al., Dose-dense cisplatin-based chemotherapy and surgery for children with high-risk hepatoblastoma (SIO-PEL-4): a prospective, single-arm, feasibility study, Lancet Oncol, vol.14, pp.834-842, 2013.

G. Curigliano, D. Cardinale, S. Dent, C. Criscitiello, O. Aseyev et al., Cardiotoxicity of anticancer treatments: epidemiology, detection, and management, CA Cancer J Clin, vol.66, pp.309-325, 2016.

S. Rebouissou, A. Franconi, J. Calderaro, E. Letouze, S. Imbeaud et al., Genotype-phenotype correlation of CTNNB1 mutations reveals different beta-catenin activity associated with liver tumor progression, Hepatology, vol.64, pp.2047-2061, 2016.

A. De-la-coste, B. Romagnolo, P. Billuart, C. A. Renard, M. A. Buendia et al., Somatic mutations of the beta-catenin gene are frequent in mouse and human hepatocellular carcinomas, Proc Natl Acad Sci U S A, vol.95, pp.8847-8851, 1998.

H. Clevers and R. Nusse, Wnt/beta-catenin signaling and disease, Cell, vol.149, pp.1192-1205, 2012.

P. Polakis, Drugging Wnt signalling in cancer, EMBO J, vol.31, pp.2737-2746, 2012.

Z. Li and T. M. Rana, Therapeutic targeting of microRNAs: current status and future challenges, Nat Rev Drug Discov, vol.13, pp.622-638, 2014.

J. K. Lam, M. Y. Chow, Y. Zhang, and S. W. Leung, siRNA versus miRNA as therapeutics for gene silencing, Mol Ther Nucleic Acids, vol.4, p.252, 2015.

S. Cairo, Y. Wang, A. De-reynies, K. Duroure, J. Dahan et al., Stem cell-like micro-RNA signature driven by Myc in aggressive liver cancer, Proc Natl Acad Sci U S A, vol.107, pp.20471-20476, 2010.

A. Magrelli, G. Azzalin, M. Salvatore, M. Viganotti, F. Tosto et al., Altered microRNA expression patterns in hepatoblastoma patients, Transl Oncol, vol.2, pp.157-163, 2009.

J. Von-frowein, P. Pagel, R. Kappler, V. Schweinitz, D. Roscher et al., MicroRNA-492 is processed from the keratin 19 gene and up-regulated in metastatic hepatoblastoma, Hepatology, vol.53, pp.833-842, 2011.

O. Saydam, Y. Shen, T. Wurdinger, O. Senol, E. Boke et al., Downregulated microRNA-200a in meningiomas promotes tumor growth by reducing E-cadherin and activating the Wnt/ beta-catenin signaling pathway, Mol Cell Biol, vol.29, pp.5923-5940, 2009.

N. H. Kim, H. S. Kim, N. G. Kim, I. Lee, H. S. Choi et al., p53 and microRNA-34 are suppressors of canonical Wnt signaling, Sci Signal, vol.4, p.71, 2011.

A. Veronese, R. Visone, J. Consiglio, M. Acunzo, L. Lupini et al., Mutated beta-catenin evades a microRNA-dependent regulatory loop, Proc Natl Acad Sci U S A, vol.108, pp.4840-4845, 2011.

X. Wang, J. Chen, F. Li, Y. Lin, X. Zhang et al., MiR-214 inhibits cell growth in hepatocellular carcinoma through suppression of beta-catenin, Biochem Biophys Res Commun, vol.428, pp.525-531, 2012.

M. Maurel, S. Jalvy, Y. Ladeiro, C. Combe, L. Vachet et al., A functional screening identifies five microRNAs controlling glypican-3: role of miR-1271 down-regulation in hepatocellular carcinoma, Hepatology, vol.57, pp.195-204, 2013.

B. Laloo, D. Simon, V. Veillat, D. Lauzel, V. Guyonnet-duperat et al., Analysis of post-transcriptional regulations by a functional, integrated, and quantitative method, Mol Cell Proteomics, vol.8, pp.1777-1788, 2009.

S. Jalvy-delvaille, M. Maurel, V. Majo, N. Pierre, S. Chabas et al., Molecular basis of differential target regulation by miR-96 and miR-182: the glypican-3 as a model, Nucleic Acids Res, vol.40, pp.1356-1365, 2012.

A. Gougelet, C. Sartor, L. Bachelot, C. Godard, C. Marchiol et al., Antitumour activity of an inhibitor of miR-34a in liver cancer with beta-catenin-mutations, Gut, vol.65, pp.1024-1034, 2016.

A. Thiele, Y. Nagamine, S. Hauschildt, and H. Clevers, AU-rich elements and alternative splicing in the beta-catenin 3 0 UTR can influence the human beta-catenin mRNA stability, Exp Cell Res, vol.312, pp.2367-2378, 2006.

J. M. Schnater, E. Bruder, S. Bertschin, T. Woodtli, C. De-theije et al., Subcutaneous and intrahepatic growth of human hepatoblastoma in immunodeficient mice, J Hepatol, vol.45, pp.377-386, 2006.

I. A. Asangani, B. Ateeq, Q. Cao, L. Dodson, M. Pandhi et al., Characterization of the EZH2-MMSET histone methyltransferase regulatory axis in cancer, Mol Cell, vol.49, pp.80-93, 2013.

M. Hagedorn, S. Javerzat, D. Gilges, A. Meyre, B. De-lafarge et al., Accessing key steps of human tumor progression in vivo by using an avian embryo model, Proc Natl Acad Sci U S A, vol.102, pp.1643-1648, 2005.

L. Dumartin, C. Quemener, H. Laklai, J. Herbert, R. Bicknell et al., Netrin-1 mediates early events in pancreatic adenocarcinoma progression, acting on tumor and endothelial cells, Gastroenterology, vol.138, pp.1591-1598, 2010.
URL : https://hal.archives-ouvertes.fr/inserm-00505056

M. Subramanian, P. Francis, S. Bilke, X. L. Li, T. Hara et al., A mutant p53/let-7i-axis-regulated gene network drives cell migration, invasion and metastasis, Oncogene, vol.34, pp.1094-1104, 2015.

A. M. Barsotti, R. Beckerman, O. Laptenko, K. Huppi, N. J. Caplen et al., p53-dependent induction of PVT1 and miR-1204, J Biol Chem, vol.287, pp.2509-2519, 2012.

E. A. Afanasyeva, P. Mestdagh, C. Kumps, J. Vandesompele, V. Ehemann et al., MicroRNA miR-885-5p targets CDK2 and MCM5, activates p53 and inhibits proliferation and survival, Cell Death Differ, vol.18, pp.974-984, 2011.
URL : https://hal.archives-ouvertes.fr/hal-00608714

T. Bou-kheir, E. Futoma-kazmierczak, A. Jacobsen, A. Krogh, L. Bardram et al., miR-449 inhibits cell proliferation and is down-regulated in gastric cancer, Mol Cancer, vol.10, p.29, 2011.

D. Hanahan and R. A. Weinberg, Hallmarks of cancer: the next generation, Cell, vol.144, pp.646-674, 2011.

C. Dias, J. Feng, H. Sun, N. Y. Shao, M. S. Mazei-robison et al., beta-catenin mediates stress resilience through Dicer1/microRNA regulation, Nature, vol.516, pp.51-55, 2014.

X. Yang, M. Feng, X. Jiang, Z. Wu, Z. Li et al., miR-449a and miR-449b are direct transcriptional targets of E2F1 and negatively regulate pRb-E2F1 activity through a feedback loop by targeting CDK6 and CDC25A, Genes Dev, vol.23, pp.2388-2393, 2009.

Z. Su, X. K. Hou, and Q. P. Wen, Propofol induces apoptosis of epithelial ovarian cancer cells by upregulation of microRNA let-7i expression, Eur J Gynaecol Oncol, vol.35, pp.688-691, 2014.

J. E. Zuckerman and M. E. Davis, Clinical experiences with systemically administered siRNA-based therapeutics in cancer, Nat Rev Drug Discov, vol.14, pp.843-856, 2015.